| Methods | D: parallel C: unclear B: double WD: 7/39 J: 0‐2‐1 DU: 1m/4m/3m | |
| Participants | N: 39/38 D: 8 migraine with, 31 without aura C: own F: 67% A: mean 39 years DU: not reported S: 7 neurologists in Switzerland | |
| Interventions | P: 120 mg C: 5‐hydroxytryptophan 300 mg | |
| Outcomes | R: 7/20 vs. 8/19 F: reduction from 7.1 (sd 5.8) vs. 9.4 (5.7) to 4.4 (4.0) vs. 7.3 (7.4) AU: reduction from 16.3 (sd 20.1) vs. 9.1 (7.4) to 4.3 (3.4) vs. 5.0 (5.5) HI: not reported AEs: 7/20 vs. 7/19 Dropouts‐AEs: 2/20 vs. 0/19 V: 0 | |
| Notes | Relevant baseline differences, high attack frequency | |
| Risk of bias | ||
| Bias | Authors' judgement | Support for judgement |
| Allocation concealment (selection bias) | Unclear risk | B ‐ Unclear |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.